Nyxoah Announces the Signature of a Memorandum of Understanding with Sheikh Shakhbout Medical City Hospital to Improve OSA Therapy Management and Accelerate Access to Genio in the Middle East
Rhea-AI Summary
Nyxoah (NASDAQ: NYXH) signed a Memorandum of Understanding with Sheikh Shakhbout Medical City on February 18, 2026 to expand access to Genio hypoglossal nerve stimulation therapy in the Middle East.
The MoU targets development of a high-volume implant program, a regional training hub for surgeons and sleep physicians, and exploration of clinical research linking OSA management to chronic and metabolic diseases.
Positive
- None.
Negative
- None.
News Market Reaction – NYXH
On the day this news was published, NYXH declined 4.51%, reflecting a moderate negative market reaction. Argus tracked a peak move of +5.8% during that session. Argus tracked a trough of -2.4% from its starting point during tracking. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $10M from the company's valuation, bringing the market cap to $213M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
NYXH was up 1.35% while momentum peers ZTEK, STXS and INFU each moved down (scanner median about -0.7%), indicating stock-specific dynamics despite broader sector pressure.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 21 | Capacity expansion | Positive | +1.1% | Investment to expand Belgian manufacturing capacity for global Genio demand. |
| Jan 12 | Preliminary earnings | Positive | -0.4% | Strong Q4 and FY2025 revenue growth and Q1 2026 guidance update. |
| Jan 12 | Transparency filing | Neutral | -0.4% | Disclosure of BNP Paribas Asset Management crossing the 3% voting threshold. |
| Dec 29 | Conference appearance | Positive | +6.3% | Announcement of presentation at the 44th J.P. Morgan Healthcare Conference. |
| Dec 19 | Convertible financing | Negative | -2.1% | First tranche of convertible bonds to fund commercialization and R&D. |
Positive strategic and financing news has generally aligned with modestly positive or mixed price reactions, with one notable divergence on strong preliminary results.
Over the last few months, Nyxoah has combined financing, growth and visibility milestones. On Dec 19, 2025, it issued a first tranche of €22.5M convertible bonds, followed by a J.P. Morgan conference appearance on Dec 29, 2025 that coincided with a 6.26% gain. January 2026 brought a transparency notification and strong preliminary 2025 results, including net revenue of about €10.0M, plus a manufacturing expansion announcement on Jan 21, 2026. Today’s Middle East MoU extends that expansion theme into regional market access and training.
Market Pulse Summary
This announcement establishes a Memorandum of Understanding with Sheikh Shakhbout Medical City to build a regional Genio therapy center and training hub in the Middle East. It complements earlier steps such as manufacturing expansion and FY2025 revenue reaching about €10.0M. Investors may watch how many surgeons and centers are ultimately trained, actual implant volumes, and how this regional strategy interacts with previously disclosed equity and convertible financings needed to support commercialization.
Key Terms
obstructive sleep apnea medical
osa medical
neuromodulation medical
hypoglossal nerve stimulation medical
memorandum of understanding regulatory
type 2 diabetes medical
AI-generated analysis. Not financial advice.
Nyxoah Announces the Signature of a Memorandum of Understanding with Sheikh Shakhbout Medical City Hospital to Improve OSA Therapy Management and Accelerate Access to Genio in the Middle East
Mont-Saint-Guibert, Belgium – February 18, 2026, 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced continued progress in strengthening its presence in the Middle East through the signature of a Memorandum of Understanding (MoU) with Sheikh Shakhbout Medical City (SSMC), a flagship hospital in the United Arab Emirates for serious and complex care and a subsidiary of PureHealth, the largest healthcare group in the Middle East. This MoU reflects Nyxoah’s strategic focus on working with leading regional medical centers to expand access to its Genio® hypoglossal nerve stimulation (HGNS) therapy, while supporting the highest standards of clinical care, education, and scientific collaboration.
As part of this MoU, Nyxoah and SSMC are engaged in initiatives aimed at positioning SSMC as a leading regional center for Genio therapy. These efforts are intended to support the development of a high-volume implant program with a strong focus on patient-centered care.
In parallel, the collaboration includes plans to establish SSMC as a regional training hub for Genio therapy in the Middle East to support the education of surgeons, sleep physicians, and referring healthcare professionals from across the region.
Nyxoah and SSMC are also engaged in discussions to explore clinical research and collaboration in the field of sleep apnea, chronic and metabolic disease management.
Olivier Taelman, Chief Executive Officer of Nyxoah, commented: “Given the high prevalence of Obstructive Sleep Apnea in the Middle East, this initiative supports our vision to offer new treatment options to patients in the region and further explore the impact of advanced OSA management on chronic and metabolic diseases such as type 2 diabetes. Our active engagement with Sheikh Shakhbout Medical City reflects our strategy of partnering with leading institutions to build sustainable clinical programs, support physician education, and contribute to the advancement of care for patients living with obstructive sleep apnea.”
Dr. Marwan Al Kaabi, Chief Executive Officer of Sheikh Shakhbout Medical City, added: “At Sheikh Shakhbout Medical City, we are committed to advancing specialized, high-quality care through clinical excellence, education, and research. Our collaboration with Nyxoah supports our efforts to further develop expertise in innovative sleep apnea therapies and to serve as a regional reference center for training and scientific exchange.”
About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.
Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and receipt of approval from the FDA for a subset of adult patients with moderate to severe OSA with an AHI of greater than or equal to 15 and less than or equal to 65.
For more information, please visit http://www.nyxoah.com/.
Caution – CE marked since 2019. FDA approved in August 2025 as prescription-only device.
Forward-looking statements
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ or management’s current expectations regarding the Genio system; the potential advantages of the Genio system; Nyxoah’s goals with respect to the potential use of the Genio system; the Company's commercialization strategy and entrance to the U.S. market; the Company's results of operations, financial condition, liquidity, performance, prospects, growth, future revenue and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”) on March 20, 2025 and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward- looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
Contacts:
Nyxoah
John Landry, CFO
IR@nyxoah.com
Rémi Renard
Head of Investor Relations & Corporate Communication
IR@nyxoah.com
Attachment
FAQ
What did Nyxoah (NYXH) announce with Sheikh Shakhbout Medical City on February 18, 2026?
How will the Nyxoah and SSMC MoU affect access to Genio therapy in the Middle East?
Does the Nyxoah agreement with Sheikh Shakhbout Medical City include clinical research or education for NYXH?
Will Sheikh Shakhbout Medical City become a regional training hub for Genio under the NYXH MoU?
Is the Nyxoah and SSMC agreement a binding commercial contract affecting NYXH revenues?
